Meet the Team
James C. Katzaroff
CHIEF EXECUTIVE OFFICER
James C. Katzaroff is highly regarded internationally for his proven expertise in corporate engineering as well as developing and implementing impactful senior-level corporate strategy. Mr. Katzaroff is passionate about fostering critical investment banking and private investor relationships as well as managing intricate stakeholder relationships.
Associates and clients continue to trust Mr. Katzaroff with their most critical business needs because of his passion, commitment and proven ability to be a solution provider and create win-win outcomes to the most complex issues that challenge all growth companies.
He has significant experience in the healthcare and medical fields and is a graduate of the University of California, Santa Barbara.
William J. Farley
BOARD OF DIRECTORS,
Bill Farley, has over 35 years’ experience in the Business Development, Sales and leading efforts in drug discovery, development and partnering. Prior to joining Sorrento Therapeutics, Mr. Farley began his career at Johnson and Johnson and has also held a positions at Pfizer and has held leadership positions at HitGen Ltd, Vice President, WuXi Apptec, Inc. building and leading a global BD team, VP of BD at ChemDiv where he lead numerous efforts to create new therapeutic companies in CNS, Oncology and Anti infectives.
Mr. Farley has served as a consultant to various executive management teams and advise several BODs on commercialization assets. Mr. Farley has spoken at numerous conferences and is published in variety of journals.
He received his Bachelor of Science degree in Chemistry from State University of New York, Oswego and graduate courses at Rutgers and UC Irvine.
Steven F. Penderghast
BOARD OF DIRECTORS,
Mr. Steven F. Penderghast joined the Angiosoma team in 2021 and serves as its Commercial Officer, overseeing market channel development and execution of the companies neuromuscular therapeutic applications. His 30 year career has focused on the product management, market development and commercialization of medical devices, capital equipment and biologics. Steven’s experience spans roles from clinical and regulatory affairs, product development, market development, sales management, contracting and corporate account relationship management.
Most recently, Steven served as Corporate Vice President, Health Systems & National Accounts with Becton Dickinson Inc., and Corporate Vice President National Accounts for CR Bard Inc., implementing market channel strategy and overseeing corporate relationships at the largest IDNs and GPOs in the United States. Prior to this, Steven held strategic development roles in both start-up ventures and in large global healthcare corporations. He has marketed technologies in the areas of: Vascular and Oncology Drug Delivery, Tumor Ablation, Oncology Therapeutics, Cardiovascular Intervention, Imaging, Urology, General Surgery, and Diagnostics.
He is a graduate of Pepperdine University, California, in Business Administration with an undergraduate focus in Statistics.
Robert Chicoski, CPA
CHIEF FINANCIAL OFFICER
Robert Chicoski, CPA is the Chief Financial Officer and Treasurer of GlobeStar Therapeutics Corporation
Robert Chicoski is a veteran CPA and investor who brings decades of corporate financial, tax, audit and forensic accounting experience to the GlobeStar Therapeutics team.
In the 1990’s, when two successful automobile salesmen decided to take advantage of the upcoming deregulation of electricity and natural gas, they hired Robert as CFO to write the business plan that would raise the first $ 1m. As part of the management team, he facilitated the successful purchase of a $1+ m energy online reverse auction platform. As number three shareholder in Oceanside Energy Company, Robert helped secure the first major customer, the General Services Administration of the Federal government. Robert set the company up to go public as World Energy Solutions, Inc. (WEXCH) and left the company to start a ministry for men coming out of prison.
In 2018, Robert became the US representative for Fabrizio de Silvestri, the founder of the successful treatment for M S and oversaw the progress to obtaining the U.S. patent. Today, his role on the management team includes the oversight of all financial and related matters.
Dr. Leonard Wisneski, MD
MEDICAL ADVISORY BOARD
Leonard A. Wisneski, MD, FACP is Clinical Professor of Medicine at George Washington University, Adjunct Faculty in the Department of Biochemistry and Molecular Biology at Georgetown University and also holds faculty positions in the Medicine and Nursing Departments at The University of Colorado. He has been in the clinical practice of endocrinology and for over 30 years and is a recognized leader globally in the field of integrative and whole person health.
Dr. Wisneski holds fellowship positions in The American College of Physicians and The American College of Nutrition. He was Chairman of the National Institute of Health (NIH) Advisory Board on Frontier Sciences at the University of Connecticut and Vice Chairman of the NIH Consensus Panel on Acupuncture. He has published over 30 scientific articles and a textbook, “Scientific Basis of Integrative Health, Third Edition.”
Dr. Wisneski is Chairman Emeritus of the Integrative Health Policy Consortium which promotes national legislation pertaining to integrative healthcare. His medical practice in endocrinology and integrative medicine, spanning three decades, embodies the true meaning of integrative healthcare – an optimal combination of conventional and complementary medicine practiced with a whole-person approach delivered with reverence and humanism. He is also a donor to the Strauss -Wisneski Indigenous and Integrative Medicine Collection housed within the Strauss Health Sciences Library at The University of Colorado.
Dr. Wisneski graduated from Thomas Jefferson Medical College and performed his postgraduate training in the field of Internal Medicine and Endocrinology in the George Washington University healthcare system, where he served as Chief Medical Resident in Internal Medicine.